ClinicalTrials.gg
CompletedNCT05077722PISTACHIoUpdated Mar 22, 2024

Monitoring of Sleep and Behavior of Children 3-7 Years Old Receiving Parent-Child Interaction Therapy With the Help of Artificial Intelligence

An interventional study of Garmin in Disruptive Behavior, Attention-deficit Hyperactivity and Oppositional Defiant Disorder, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 3 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
3 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to develop an innovative wearable tracking protocol that will use Artificial Intelligence (AI) technology to monitor sleep and behavior of 3-7 year old children.

02

Conditions studied

  • Disruptive Behavior
  • Attention-deficit Hyperactivity
  • Oppositional Defiant Disorder

Keywords

  • Emotional Behavioral Dyscontrol
03

In context

Problem Behavior

178 studies on the registry are indexed under Problem Behavior; 47 are open to participants now.

This study's enrollment of 100 is above the median of 90 across 165 interventional studies indexed under Problem Behavior.

Browse Problem Behavior studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Children:

  • Ages 3-7.
  • Outpatients or Inpatients.
  • Any gender, race or ethnicity.
  • Able to provide developmentally appropriate informed assent, and legal guardians able to provide .
  • EBP Severity rated above the range (≥120; T-score ≥ 60) (Eyberg Child Behavior Inventory- ECBI; Eyberg \& Pincus, 1999).
  • Need for more intensive behavioral treatments such as ER visit for behavioral dyscontrol or hospitalization will not be exclusionary or exit criteria.
  • Families approached for participation will be asked to commit to complete the treatment.
  • At least one primary caregiver and the identified child will have to be able to speak and understand English.

Exclusion Criteria - Children:

  • Formal diagnosis of Severe Intellectual disability, Autistic Spectrum Disorder Level 3, or a psychotic disorder for the child.
  • Parents not consenting to the study.
  • Parents or child is not able to adhere to the study protocol.
  • A Child who is reasonable expected to be unable to tolerate wearing the Garmin device for at least 70% of the time during the day and night 70% of the days during the treatment (12 weeks). This is based on the principal investigator's discretion.
  • Unable to speak and understand English.
  • Refusal or withdrawal of consent, inability, or unwillingness to adhere to study procedures.
  • Children in foster care.

Inclusion Criteria - Adults:

  • Agree to wear Garmin watch.
  • Ages 18-99.
  • Any gender, race, ethnicity.
  • Able to provide informed consent.

Exclusion Criteria - Adults:

  • Unable to speak and understand English.
  • Refusal or withdrawal of consent, inability, or unwillingness to adhere to study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    AI Parent Child Interaction Therapy

    Subjects enrolled in Parent Child Interaction Therapy (PCIT) will wear a Garmin smartwatch that will provided targeted messages during tantrums picked up by the Garmin devices that will instruct them on how to deescalate their child.

    Device: Garmin

  • Sham comparator
    Sham Biometric - Parent Child Interaction Therapy

    Subjects enrolled in Parent Child Interaction Therapy will wear Garmin smartwatch and will receive only random messages throughout the day with various relaxation strategies such as reminders to practice deep breathing with their child.

    Device: Garmin

Interventions

  • DeviceGarmin

    A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.

06

What researchers measure

Primary outcomes

  1. Frequency of Garmin use

    Number of days participants wear the Garmin smartwatch

    Time frame: 12 weeks

Secondary outcomes

  1. Eyberg Child Behavior Inventory

    The Eyberg Child Behavior Inventory questionnaire is measured on two subscales for a series of phrases that describe a children's behavior. The first subscale is for indicating the frequency of the behavior using a scale of 1= never to 7 = Always; the second subscale indicates yes = 1 or no = 0 for whether the behavior is currently a problem for them. Reponses are total with a higher score indicating greater severity of child's behavior.

    Time frame: 12 weeks

  2. Pediatric Sleep Questionnaire

    Pediatric Sleep Questionnaire to assess child's sleep with a series of 22 questions on a yes/no problem scale.

    Time frame: 12 weeks

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2023, 20 months.

Of 111 non-industry interventional studies with no phase under Problem Behavior, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 20 months is below that.

Counting every sponsor, half of 112 studies reached it within 24 months; a quarter within 13 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2021
First posted
Oct 14, 2021
StartActual
Mar 24, 2022
Primary completionActual
Dec 1, 2023
CompletionActual
Dec 1, 2023
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05077722
Lead sponsor
Mayo Clinic
Responsible party
Paul E. Croarkin (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 14, 2021
Start date
Mar 24, 2022
Primary completion
Dec 1, 2023
Completion
Dec 1, 2023
Last update
Mar 22, 2024

Study contacts

Paul Croarkin, DO, MS
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion